ArticleJournal of multidisciplinary healthcare2025
Visualising the Knowledge Structure of Microglia in Alzheimer's Disease: A CiteSpace Analysis.
Article in Journal of multidisciplinary healthcare, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Alzheimer's disease (AD) is a growing global health burden, yet effective therapies remain elusive. Microglia-the brain's resident immune cells-have emerged as key players in AD, capable of both neuroprotection and neurotoxicity. To elucidate research progress and gaps, we conducted a bibliometric analysis of global studies on "microglia and AD" from 2010 to 2025, highlighting advances beyond prior reviews. Methods: We searched the Web of Science Core Collection for relevant publications (2010-2025). After screening and deduplication, 12,275 records were analysed with CiteSpace 6.2.R4 to generate co-citation networks, keyword clusters, citation-burst timelines, and collaboration maps at national, institutional, and author levels. Results: Annual output rose markedly, peaking in 2022. The United States and China led the field; Harvard University, the University of California System, and the Chinese Academy of Sciences were the most prolific institutions. Influential authors included Holtzman, Heneka, Zetterberg, and Colonna. Co-citation analysis revealed three dominant knowledge clusters: microglial activation, TREM2-mediated immune responses, and neuroinflammation. Keyword evolution showed growing attention to TREM2 variants, NLRP3 inflammasome, single-cell omics, and novel imaging techniques, reflecting a shift toward microglial heterogeneity and translational research. Conclusion: Microglia occupy a central position in AD pathogenesis through intertwined molecular pathways and dynamic functional states. Future work should refine subtype-specific roles, integrate peripheral-central immune interactions, and accelerate the translation of mechanistic insights into targeted interventions. This bibliometric overview maps collaboration patterns and emerging themes, providing a strategic guide for researchers aiming to advance microglia-focused AD therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.